[HTML][HTML] The landscape of signaling pathways and proteasome inhibitors combinations in multiple myeloma

T Paradzik, C Bandini, E Mereu, M Labrador, E Taiana… - Cancers, 2021 - mdpi.com
… as compared to the lenalidomide-bortezomib combination [21]. … the combination of perifosine
with bortezomib blocks AKT … synergistic to bortezomib [161,162], antimyeloma activity has …

[HTML][HTML] Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma

R Suzuki, Y Kitamura, Y Nakamura, H Akashi… - Oncotarget, 2020 - ncbi.nlm.nih.gov
… with bortezomib, lenalidomide, or other novel agents in multiple myeloma (MM) cells in … or
in combination with novel drugs showed significant anti-myeloma effects on MM cells in vitro, …

[HTML][HTML] Future developments in the treatment of AL amyloidosis

F Theodorakakou, D Fotiou, MA Dimopoulos… - Hemato, 2022 - mdpi.com
anti-myeloma agents. It is still early to assess whether these … evaluated the combination of
perifosine with bortezomib and … and 27% discontinued lenalidomide due to toxicity which was …

[HTML][HTML] Pathway-directed therapy in multiple myeloma

L John, MT Krauth, K Podar, MS Raab - Cancers, 2021 - mdpi.com
perifosine and might be at least partly due to lenalidomide [79]. Another phase I/II-trial testing
perifosine in combination with bortezomib … Potent in vitro anti-myeloma activity was induced …

CDK9 inhibitors in multiple myeloma: a review of progress and perspectives

B Jędrzej, S Krzysztof, A Navid, S Łukasz - Medical Oncology, 2022 - search.proquest.com
… dependent cytotoxicity in Doxorubicinresistant, Lenalidomide… -vitro study showed that although
significant anti-myeloma effects … with perifosine against Akt. J Hematol Oncol. 2013;6:18. …

[HTML][HTML] Disulfiram/copper markedly induced myeloma cell apoptosis through activation of JNK and intrinsic and extrinsic apoptosis pathways

Y Xu, Q Zhou, X Feng, Y Dai, Y Jiang, W Jiang… - Biomedicine & …, 2020 - Elsevier
drugs such as proteasome inhibitors (eg, bortezomib and carfizomib), immunomodulatory
drugs (eg, thalidomide and lenalidomide)… as a potent anti-myeloma agent in vitro and in animal …

From mechanism to resistance–changes in the use of dexamethasone in the treatment of multiple myeloma

AS Rosenberg - Leukemia & Lymphoma, 2023 - Taylor & Francis
… or SD improved response in both bortezomib-relapsed and refractory patients … In this study
of 445 patients, lenalidomide plus low-dose … In addition to demonstrated anti-myeloma activity, …

[HTML][HTML] CDK9 inhibitors in multiple myeloma: a review of progress and perspectives

J Borowczak, K Szczerbowski, N Ahmadi, Ł Szylberg - Medical oncology, 2022 - Springer
… dose-dependent cytotoxicity in Doxorubicin-resistant, Lenalidomide-resistant and Bortezomib-…
The subsequent in-vitro study showed that although significant anti-myeloma effects were …

Resistance to the proteasome inhibitors: Lessons from multiple myeloma and mantle cell lymphoma

M Gonzalez-Santamarta, G Quinet… - … and Disease: From …, 2020 - Springer
… immunomodulatory drugs (IMiDs) such as lenalidomide or … inhibiting activity displayed
promising anti-myeloma activity [80]. … perifosine combined with BTZ revealed increase cytotoxicity

[HTML][HTML] Signaling pathway mediating myeloma cell growth and survival

T Hideshima, KC Anderson - Cancers, 2021 - mdpi.com
… Akt inhibitor perifosine induces significant cytotoxicity in MM … - or proteasome inhibitor
bortezomib-induced cytotoxicity [30]. … -tolerated dose of perifosine-lenalidomide-dexamethasone …